Press Release
12 November 2026 08:23:00 CET

Affibody Establishes Scientific Advisory Board with Appointment of Leading Radiopharmaceutical Experts Oliver Sartor, Ken Herrmann and Peter Bernhardt

Stockholm, Sweden, November 12, 2026. Affibody Medical AB ("Affibody") today announced the establishment of a Scientific Advisory Board (SAB) to provide strategic and scientific guidance as the Company advances its pipeline of Radioligand Therapies (RLTs). The SAB will be chaired by Affibody Board member Jonathan Knowles and includes newly appointed members Oliver Sartor, Ken Herrmann and Peter Bernhardt, internationally recognized experts in oncology, radiopharmaceutical development and dosimetry.

Professor Jonathan Knowles, Ph.D., who has served on Affibody's Board of Directors since 2011 and will chair the SAB, has extensive global experience in drug discovery, development and corporate strategy. He currently holds visiting professorships at the University of Helsinki and Oxford University. He previously served as Head of Group Research at Roche and as a member of Roche's executive committee. He was also the founding chairman of the Innovative Medicines Initiative Board and has been a longstanding advocate for advancing personalized medicine and translating scientific innovation into meaningful improvements in patient care.

Oliver Sartor, M.D., is an internationally recognized medical oncologist and a leading authority in prostate cancer and radiopharmaceutical therapies. He is Director of the Transformational Prostate Cancer Research Center at East Jefferson General Hospital Cancer Center and previously served as Director of Radiopharmaceutical Clinical Trials at the Mayo Clinic. Dr. Sartor has played a pivotal role in the clinical development of multiple transformative oncology therapies, including Xofigo® (radium-223), Pluvicto® (¹##Lu-PSMA-617), Jevtana® (cabazitaxel), and Quadramet® (samarium-153). He has authored more than 600 peer-reviewed publications.

Ken Herrmann, M.D., is Professor of Nuclear Medicine at the University Hospital Essen. He is a globally renowned expert in theranostics and nuclear medicine, with extensive experience in clinical development and translational research. Dr. Herrmann serves as Section Editor of The Journal of Nuclear Medicine and previously chaired the European Association of Nuclear Medicine (EANM) Oncology & Theranostics Committee. He has been Adjunct Professor at the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA), and Vice Chair of the Department of Nuclear Medicine at University Hospital Würzburg.

Peter Bernhardt, Ph.D., is Professor at the Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, and an internationally recognized expert in radiopharmaceutical therapy and dosimetry. His research focuses on the development and clinical translation of radiopharmaceutical therapies, including imaging, dosimetry and response modelling to individualize and optimize cancer treatment. He has authored numerous publications in nuclear medicine and radiopharmaceutical therapy.

"We are delighted to welcome Drs. Sartor, Herrmann and Bernhardt to Affibody's Scientific Advisory Board," said David Bejker, CEO of Affibody. "Together with Professor Knowles, they bring exceptional and highly complementary expertise across radiopharmaceutical discovery and development, from translational science and dosimetry through clinical development and patient care. Their guidance will be invaluable as we advance our pipeline and continue building Affibody into a leading radiopharmaceutical company."

About Affibody

Affibody is a clinical stage radiopharmaceutical company developing next generation Radioligand Therapies (RLTs) designed to deliver highly selective tumor targeting across a wide range of cancers. Leveraging decades of innovation in Affibody® molecule discovery and engineering, together with deep understanding of the RLT field, the company is advancing a novel pipeline focused on oncology indications with high unmet medical need. Affibody's lead RLT candidate, ABY-271, is currently being evaluated in a first-in-human clinical study in HER2-positive metastatic breast cancer.

The Affibody® platform has also demonstrated clinical value in immunology and inflammation, with multiple programs being advanced through strategic partnerships.

Affibody's main shareholder, Patricia Industries, is a part of Investor AB.

Further information can be found at: www.affibody.com.

Disclaimer

This press release contains forward-looking statements. While Affibody consider the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by several hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.

Investor Relations

Leigh Salvo, New Street Investor Relations, +1 510 693 5238, leigh@newstreetir.com

Media Contact

Richard Hayhurst, 59° North Communications, +44 (0) 7711 8215727, richard.hayhurst@59north.bio

Affibody Contact

David Bejker, CEO, +46 706 454 948
Peter Zerhouni, CFO and CBO, +46 706 420 044

Press Release
12 November 2026 08:23:00 CET

Attachments

Affibody Establishes Scientific Advisory Board with Appointment of Leading Radiopharmaceutical Experts Oliver Sartor, Ken Herrmann and Peter Bernhardt